Nautilus Biotechnology Highlights Q4 Progress, Outlines 2026 Milestones

Company unveils Voyager instrument, launches early access program, and expects revenue ramp in 2027

Published on Feb. 26, 2026

Got story updates? Submit your updates here. ›

Nautilus Biotechnology (NASDAQ:NAUT) used its fourth-quarter 2025 earnings call to highlight recent steps toward commercialization of its proteomics platform, including the public debut of its Voyager instrument and the launch of an early access program. The company also discussed continued cost reductions, updated expectations for 2026 spending and revenue, and key milestones planned for the pivotal year ahead.

Why it matters

Nautilus Biotechnology is developing a next-generation proteomics platform that aims to provide high-resolution, single-molecule protein analysis, which could accelerate drug discovery and biomarker research. The company's progress in 2025 and plans for 2026 demonstrate its transition from development to active customer engagement and commercial readiness.

The details

Key Q4 2025 milestones included the public unveiling of the Nautilus Voyager instrument at the U.S. Human Proteome Organization conference and the launch of the Iterative Mapping Early Access Program, which allows partners to submit samples, receive data, and provide feedback. The company also highlighted collaborations that generated new tau-focused data and validation, as well as advancements in its broad-scale assay and proteoform assay portfolio, including plans to enter an oncology-focused assay into early access in the second half of 2026.

  • Nautilus publicly unveiled the Voyager instrument at the U.S. Human Proteome Organization conference in Q4 2025.
  • Nautilus launched its Iterative Mapping Early Access Program in January 2026, earlier than previously communicated.
  • Nautilus expects to initiate its commercial launch in late 2026 by opening the Voyager platform for pre-orders, with instrument installations beginning in early 2027.
  • Nautilus expects to introduce broad-scale capabilities into early access later in 2026, with general availability targeted for the first half of 2027.

The players

Nautilus Biotechnology

An American life sciences company developing a next-generation proteomics platform that aims to provide high-resolution, single-molecule protein analysis.

Sujal Patel

Co-founder and CEO of Nautilus Biotechnology.

Parag Mallick

Co-founder and Chief Scientist of Nautilus Biotechnology.

Anna Mowry

Chief Financial Officer of Nautilus Biotechnology.

Birgit Schilling

Collaborator at the Allen Institute for Brain Science who presented data at US HUPO.

Got photos? Submit your photos here. ›

What they’re saying

“We must not let individuals continue to damage private property in San Francisco.”

— Robert Jenkins, San Francisco resident (San Francisco Chronicle)

“Fifty years is such an accomplishment in San Francisco, especially with the way the city has changed over the years.”

— Gordon Edgar, grocery employee (Instagram)

What’s next

The judge in the case will decide on Tuesday whether or not to allow Walker Reed Quinn out on bail.

The takeaway

This case highlights growing concerns in the community about repeat offenders released on bail, raising questions about bail reform, public safety on SF streets, and if any special laws to govern autonomous vehicles in residential and commercial areas.